Kerasia-Maria Plachouri
Research Subjects
Research Interests
Kerasia-Maria Plachouri has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Sophia Georgiou
Univ Gen Hosp Patras, Dept Dermatol, Patras, Greece
20 shared publications- Francesk Mulita
Department of General Surgery, General University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece
6 shared publications - Sophia Georgiou
Department of Dermatology-Venereology, School of Medicine, University of Patras, 26504 Patras, Greece
6 shared publications - Sophia Georgiou
Department of Dermatology, University General Hospital of Patras, Greece
4 shared publications Chrysa Oikonomou
Univ Gen Hosp Patras, Dept Dermatol, Patras, Greece
3 shared publications- Despoina Gkentzi
Department of Pediatrics, School of Medicine, University of Patras, 26504 Patras, Greece
3 shared publications
Latest Publications
- Open Access
Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
Open AccessCutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
- Open Access
- 31 May 2022
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 39 (1) , 651-655
Nipple candidiasis and painful lactation: an updated overview
Nipple pain and discomfort during or after breastfeeding remains one of the most common reasons for premature cessation of lactation among the affected women. The belief that yeasts, and especially Candida spp., are responsible for such symptoms is highly supported by many physicians, midwives,...
- 31 May 2022
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 39 (1) , 651-655
Open AccessNipple candidiasis and painful lactation: an updated overview
Nipple pain and discomfort during or after breastfeeding remains one of the most common reasons for premature cessation of lactation among the affected women. The belief that yeasts, and especially Candida spp., are responsible for such symptoms is highly supported by many physicians, midwives,...
- Open Access
- 25 February 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (7) , 748-749
The Role of the European Dermatological Associations in the Promotion of Maternity-Friendly Policies During the Dermatology Residency
- 25 February 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (7) , 748-749
Open AccessThe Role of the European Dermatological Associations in the Promotion of Maternity-Friendly Policies During the Dermatology Residency
- 31 January 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (1) , e10-e11
Mild-term outcomes in the treatment of retroperitoneal sarcomas: a 12-year single-institution experience
- 31 January 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (1) , e10-e11
Mild-term outcomes in the treatment of retroperitoneal sarcomas: a 12-year single-institution experience
- Open Access
- 1 November 2021
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 108 (5) , 292-+
Management of Pediatric Nail Psoriasis
Pediatric nail psoriasis is a condition that has not been extensively studied. The prevalence of nail alterations in pediatric patients with psoriasis varies am
- 1 November 2021
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 108 (5) , 292-+
Open AccessManagement of Pediatric Nail Psoriasis
Pediatric nail psoriasis is a condition that has not been extensively studied. The prevalence of nail alterations in pediatric patients with psoriasis varies am
- Open Access
- 28 October 2021
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 11 (4) , e2021060
Back to the Basics: Response of Alopecia Areata Universalis to Intravenous High-Dose Pulse Corticosteroid Therapy
Citation: Plachouri KM, Oikonomu C, Vryzaki E, Georgiou S. Back to the basics: response of alopecia areata universalis to intravenous high-dose pulse corticosteroid therapy. Dermatol Pract Concept. 2021;11(4):e2021060. DOI: https://doi.org/10.5826/dpc.1104a60 Accepted: December 10, 2020; Published: October, 2021 Copyright: ©2021 Plachouri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Kerasia-Maria Plachouri, University General Hospital of Patras, Patras, Greece.Email: kerasia.plachouri@hotmail.com Keywords : alopecia areata universalis, intravenous, pulse corticosteroids, remission This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- 28 October 2021
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 11 (4) , e2021060
Open AccessBack to the Basics: Response of Alopecia Areata Universalis to Intravenous High-Dose Pulse Corticosteroid Therapy
Citation: Plachouri KM, Oikonomu C, Vryzaki E, Georgiou S. Back to the basics: response of alopecia areata universalis to intravenous high-dose pulse corticosteroid therapy. Dermatol Pract Concept. 2021;11(4):e2021060. DOI: https://doi.org/10.5826/dpc.1104a60 Accepted: December 10, 2020; Published: October, 2021 Copyright: ©2021 Plachouri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Kerasia-Maria Plachouri, University General Hospital of Patras, Patras, Greece.Email: kerasia.plachouri@hotmail.com Keywords : alopecia areata universalis, intravenous, pulse corticosteroids, remission This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- 30 September 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (1) , E13-E14
The need to prevent a future where dermatologists are only left to treat acne
- 30 September 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (1) , E13-E14
The need to prevent a future where dermatologists are only left to treat acne
- Open Access
- 28 September 2021
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 11 (4) , e2021142
Virtual Dermatological Congresses: A Chance for Equality and Diversity in Continuous Medical Education
- 28 September 2021
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 11 (4) , e2021142
Open AccessVirtual Dermatological Congresses: A Chance for Equality and Diversity in Continuous Medical Education
- Open Access
- 30 April 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (4) , e241900
Remission of genital and generalised extragenital lichen sclerosus et atrophicus under pulse therapy with intravenous steroids
- 30 April 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (4) , e241900
Open AccessRemission of genital and generalised extragenital lichen sclerosus et atrophicus under pulse therapy with intravenous steroids
- 1 December 2020
- Vol. 28 (3) , 171-179
On- and Off-Label Uses of Apremilast in Dermatology.
Apremilast is an oral small-molecule phosphodiesterase 4 inhibitor with a multilevel immunomodulating mechanism of action. It has received approval in many countries for the use in moderate-to-severe plaque psoriasis and active psoriatic arthritis in adults. Herein, we review the literature concerning the use of apremilast in dermatology, with a focus on both the on- and the off-label uses of this medication in dermatologic conditions. This paper is a systematic overview of all the reported uses of apremilast in dermatology described in the literature so far and was conducted according to the PRISMA Guidelines for systematic reviews. There are several original articles, case series and case reports In the literature that present either encouraging or less promising results concerning the efficacy and safety of apremilast in numerous inflammatory dermatological diseases. Despite the potential effectiveness of apremilast in various indications, however, randomized clinical trials on larger patient cohorts and with long-term follow-up are necessary in order to adequately establish the role of apremilast in dermatology overall.
- 1 December 2020
- Vol. 28 (3) , 171-179
On- and Off-Label Uses of Apremilast in Dermatology.
Apremilast is an oral small-molecule phosphodiesterase 4 inhibitor with a multilevel immunomodulating mechanism of action. It has received approval in many countries for the use in moderate-to-severe plaque psoriasis and active psoriatic arthritis in adults. Herein, we review the literature concerning the use of apremilast in dermatology, with a focus on both the on- and the off-label uses of this medication in dermatologic conditions. This paper is a systematic overview of all the reported uses of apremilast in dermatology described in the literature so far and was conducted according to the PRISMA Guidelines for systematic reviews. There are several original articles, case series and case reports In the literature that present either encouraging or less promising results concerning the efficacy and safety of apremilast in numerous inflammatory dermatological diseases. Despite the potential effectiveness of apremilast in various indications, however, randomized clinical trials on larger patient cohorts and with long-term follow-up are necessary in order to adequately establish the role of apremilast in dermatology overall.